Skip to main content

Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies.

Smith ER, Ford ML, Tomlinson LA, Weaving G, Rocks BF, Rajkumar C, Holt SG

Publication: Clin Chim Acta (2011) • Vol 412 • Page 1008-11PMID: 21324311View on PubMed

Purpose

The purpose of this paper was to determine the effects of room temperature storage of K2EDTA whole blood and plasma, with and without protease inhibitors, on levels on intact (N-terminal) and C-terminal fibroblast growth factor (FGF)-23 in healthy individuals and patients with chronic kidney disease (CKD).

Conclusion

With storage of whole blood or plasma at room temperature, intact FGF-23 declined after 2 h and C-terminal FGF-23 increased after 30 min. Protease inhibitor cocktail completely stabilized intact and C-terminal FGF-23, but aprotinin only partially stabilized intact and C-terminal FGF-23 levels. Baseline levels of intact and C-terminal FGF-23 were 2-3 fold higher in patients with CKD than in healthy individuals, and the relative changes in intact and C-terminal FGF-23 levels with storage were larger in patients with CKD than in healthy individuals.

Studies (1)

Purpose

The purpose of this study was to determine the effects of up to 4 h room temperature storage of K2EDTA whole blood and plasma, with and without protease inhibitor cocktail or aprotinin, on levels of intact and C-terminal FGF-23 in healthy individuals and patients with CKD. After experimental storage plasma and whole blood specimens were frozen and stored at -70 degrees C prior to analysis.

Summary of Findings

Intact FGF-23 levels measured in plasma declined at similar rates when whole blood or plasma specimens were stored at room temperature for 4 h (both p<0.001). In contrast using the C-terminal assay FGF-23 increased in plasma and whole blood stored at room temperature for 2 h (both p<0.001) or more. Intact and C-terminal FGF-23 levels in both blood and plasma were stabilized for at least 4 h by the addition of protease inhibitor cocktail, but aprotinin only partially stabilized intact and C-terminal FGF-23 levels (each <30% change over 4 h). Baseline levels of intact and C-terminal FGF-23 were 2-3 fold higher in patients with CKD than in healthy individuals, and the relative changes in intact and C-terminal FGF-23 levels in unstabilized whole blood and plasma with storage were larger in patients with CKD than in healthy individuals. In stabilized specimens from healthy individuals, there was only a weak association (r2=0.186) between intact and c-terminal FGF-23 levels, but in patients with CKD, the association between intact and c-terminal FGF-23 was moderate (r2=0.428).

  • Biospecimens

    FluidBlood
    FluidPlasma
  • Preservation Types

    Frozen
  • Diagnoses

    Normal
    Other diagnoses
  • Platforms

    ProteinELISA
    PeptideELISA
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Chronic kidney disease
    Healthy
    Biospecimen Aliquots and ComponentsBlood and blood products
    Plasma
    Whole blood
    StorageTime at room temperature
    2 h
    30 min
    4 h
    Analyte Extraction and PurificationProtease inhibitor
    Aprotinin
    Cocktail
    ELISA SpecificTargeted peptide/protein
    C-terminal FGF-23
    N-terminal FGF-23